HMGB1 as a Key Mediator of Immune Mechanisms in Ischemic Stroke

Antioxidants and Redox Signaling

Volumn 24, Issue 12, 2016, Pages 635-651

  Singh, Vikramjeet ^a,b   Roth, Stefan ^a,b   Veltkamp, Roland ^c   Liesz, Arthur ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Germany 3 Munich Cluster for Systems Neurology   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR; HMGB1 PROTEIN, HUMAN;

BRAIN INJURY; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; EXPERIMENTAL CEREBRAL ISCHEMIA; EXPERIMENTAL STROKE; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOMODULATION; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; CEREBROVASCULAR ACCIDENT; IMMUNOLOGY; METABOLISM;

BRAIN ISCHEMIA; HMGB1 PROTEIN; HUMANS; INFLAMMATION; STROKE;

EID: 84966351251     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6397     Document Type: Review

References (146)

1. Afshar-Kharghan V and Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 13: 34-39, 2006.
2. Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, and Herold KC. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One 7: e34698, 2012.
3. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, and Zychlinsky A. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285: 736-739, 1999.
4. An C, Shi Y, Li P, Hu X, Gan Y, Stetler RA, Leak RK, Gao Y, Sun BL, Zheng P, and Chen J. Molecular dialogs between the ischemic brain and the peripheral immune system: Dualistic roles in injury and repair. Prog Neurobiol 115C: 6-24, 2014.
5. Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, and Ferdinandy P. The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol 172: 1587-1606, 2015.
6. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue LF, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, and Du Yan SS. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23: 4096-4105, 2004.
7. Balosso S, Liu J, Bianchi ME, and Vezzani A. Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. Antioxid Redox Signal 21: 1726-1740, 2014.
8. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, and Feuerstein GZ. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 28: 1233-1244, 1997.
9. Barone FC, Schmidt DB, Hillegass LM, Price WJ, White RF, Feuerstein GZ, Clark RK, Lee EV, Griswold DE, and Sarau HM. Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia. Stroke 23: 1337-1347; discussion 1347-1348, 1992.
10. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, and Nawroth PP. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83: 876-886, 2005.
11. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, and Offner H. IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis 28: 375-386, 2013.
12. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, and Offner H. Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis 29: 59-73, 2014.
13. Bonita R. Epidemiology of stroke. Lancet 339: 342-344, 1992.
14. Bonita R, Solomon N, and Broad JB. Prevalence of stroke and stroke-related disability. Estimates from the Auckland stroke studies. Stroke 28: 1898-1902, 1997.
15. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, and Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462, 2000.
16. Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol 6: 111-130, 2006.
17. Brea D, Blanco M, Ramos-Cabrer P, Moldes O, Arias S, Perez-Mato M, Leira R, Sobrino T, and Castillo J. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab 31: 1424-1431, 2011.
18. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19: 5237-5246, 1999.
19. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2: 396-409, 2005.
20. Carty M and Bowie AG. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 81: 825-837, 2011.
21. Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, and Veltkamp R. The immunology of acute stroke. Nat Rev Neurol 8: 401-410, 2012.
22. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 59: 791-808, 2010.
23. Chapman KZ, Dale VQ, Denes A, Bennett G, Rothwell NJ, Allan SM, and McColl BW. A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. J Cereb Blood Flow Metab 29: 1764-1768, 2009.
24. Cohen JE, Leker RR, and Rabinstein A. New strategies for endovascular recanalization of acute ischemic stroke. Neurol Clin 31: 705-719, 2013.
25. Coull AJ, Lovett JK, Rothwell PM, and Oxford Vascular S. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328: 326, 2004.
26. Couper KN, Blount DG, and Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 180: 5771-5777, 2008.
27. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, and Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913, 2003.
28. del Zoppo GJ. Acute anti-inflammatory approaches to ischemic stroke. Ann N Y Acad Sci 1207: 143-148, 2010.
29. Denes A, Wilkinson F, Bigger B, Chu M, Rothwell NJ, and Allan SM. Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice. Dis Model Mech 6: 1043-1048, 2013.
30. Ooboshi H, Ibayashi S, Shichita T, Kumai Y, Takada J, Ago T, Arakawa S, Sugimori H, Kamouchi M, Kitazono T, and Iida M. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 111: 913-919, 2005.
31. Ding Q and Keller JN. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim Biophys Acta 1746: 18-27, 2005.
32. Downes CE, Wong CH, Henley KJ, Guio-Aguilar PL, Zhang M, Ates R, Mansell A, Kile BT, and Crack PJ. MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke. PLoS One 8: e57948, 2013.
33. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, and Rovere-Querini P. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174: 7506-7515, 2005.
34. Elenkov IJ, Papanicolaou DA, Wilder RL, and Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 108: 374-381, 1996.
35. Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, Illingworth K, Scarth S, Wickramasinghe V, Hoadley ME, Rothwell NJ, Tyrrell PJ, and Hopkins SJ. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol 7: 5, 2007.
36. Engel O, Kolodziej S, Dirnagl U, and Prinz V. Modeling stroke in mice - middle cerebral artery occlusion with the filament model. J Vis Exp 2423, 2011.
37. Famakin BM, Mou Y, Ruetzler CA, Bembry J, Maric D, and Hallenbeck JM. Disruption of downstream MyD88 or TRIF Toll-like receptor signaling does not protect against cerebral ischemia. Brain Res 1388: 148-156, 2011.
38. Fan J, Li Y, Levy RM, Fan JJ, Hackam DJ, Vodovotz Y, Yang H, Tracey KJ, Billiar TR, and Wilson MA. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol 178: 6573-6580, 2007.
39. Fang P, Pan HC, Lin SL, Zhang WQ, Rauvala H, Schachner M, and Shen YQ. HMGB1 contributes to regeneration after spinal cord injury in adult zebrafish. Mol Neurobiol 49: 472-483, 2014.
40. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, Moroni F, and Chiarugi A. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 103: 590-603, 2007.
41. Feigin VL, Lawes CM, Bennett DA, and Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2: 43-53, 2003.
42. Gao TL, Yuan XT, Yang D, Dai HL, Wang WJ, Peng X, Shao HJ, Jin ZF, and Fu ZJ. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J Trauma Acute Care Surg 72: 643-649, 2012.
43. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, and Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3: 995-1001, 2002.
44. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeisser A, Yilmaz A, Ludwig J, Neundörfer B, and Daniel WG. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34: 1412-1418, 2003.
45. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, and Magnus T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40: 1849-1857, 2009.
46. Gendron A, Teitelbaum J, Cossette C, Nuara S, Dumont M, Geadah D, du Souich P, and Kouassi E. Temporal effects of left versus right middle cerebral artery occlusion on spleen lymphocyte subsets and mitogenic response in Wistar rats. Brain Res 955: 85-97, 2002.
47. Gesuete R, Kohama SG, and Stenzel-Poore MP. Toll-like receptors and ischemic brain injury. J Neuropathol Exp Neurol 73: 378-386, 2014.
48. Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, and Donnan GA. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc Dis 20: 239-244, 2005.
49. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, and Tracey KJ. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25: 571-574, 2006.
50. Gong G, Xiang L, Yuan L, Hu L, Wu W, Cai L, Yin L, and Dong H. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. PLoS One 9: e89450, 2014.
51. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, and Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317-1329, 2008.
52. Hanisch UK. Microglia as a source and target of cytokines. Glia 40: 140-155, 2002.
53. Hayakawa K, Nakano T, Irie K, Higuchi S, Fujioka M, Orito K, Iwasaki K, Jin G, Lo EH, Mishima K, and Fujiwara M. Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 30: 871-882, 2010.
54. Hayakawa K, Qiu J, and Lo EH. Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 1207: 50-57, 2010.
55. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. JBiolChem270: 25752-25761, 1995.
56. Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G, Liesz A, and Veltkamp R. Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 40: 3226-3232, 2009.
57. Hug A, Liesz A, Muerle B, Zhou W, Ehrenheim J, Lorenz A, Dalpke A, and Veltkamp R. Reduced efficacy of circulating costimulatory cells after focal cerebral ischemia. Stroke 42: 3580-3586, 2011.
58. Iadecola C and Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 17: 796-808, 2011.
59. Ito D, Tanaka K, Suzuki S, Dembo T, and Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32: 1208-1215, 2001.
60. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, and Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 72: 3290-3301, 2012.
61. Kamide T, Kitao Y, Takeichi T, Okada A, Mohri H, Schmidt AM, Kawano T, Munesue S, Yamamoto Y, Yamamoto H, Hamada J, and Hori O. RAGE mediates vascular injury and inflammation after global cerebral ischemia. Neurochem Int 60: 220-228, 2012.
62. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, and Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29: 21-32, 2008.
63. Kim JB, Lim CM, Yu YM, and Lee JK. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 86: 1125-1131, 2008.
64. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, and Lee JK. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26: 6413-6421, 2006.
65. Konsman JP, Drukarch B, and Van Dam AM. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin Sci (Lond) 112: 1-25, 2007.
66. Koyama H, Yamamoto H, and Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 13: 625-635, 2007.
67. Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B, Youssef P, Yanasak N, Vender JR, and Dhandapani KM. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia 62: 26-38, 2014.
68. Lambertsen KL, Biber K, and Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 32: 1677-1698, 2012.
69. Lee SC, Liu W, Dickson DW, Brosnan CF, and Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659-2667, 1993.
70. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, and Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100: 8514-8519, 2003.
71. Li G, Liang X, and Lotze MT. HMGB1: the central cytokine for all lymphoid cells. Front Immunol 4: 68, 2013.
72. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Wang H, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, and Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9: 37-45, 2003.
73. Liesz A, Dalpke A, Mracsko E, Antoine DJ, Roth S, Zhou W, Yang H, Na SY, Akhisaroglu M, Fleming T, Eigenbrod T, Nawroth PP, Tracey KJ, and Veltkamp R. DAMP signaling is a key pathway inducing immune modulation after brain injury. J Neurosci 35: 583-598, 2015.
74. Liesz A, Hagmann S, Zschoche C, Adamek J, Zhou W, Sun L, Hug A, Zorn M, Dalpke A, Nawroth P, and Veltkamp R. The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke 40: 2849-2858, 2009.
75. Liesz A, Hu X, Kleinschnitz C, and Offner H. Functional role of regulatory lymphocytes in stroke: facts and controversies. Stroke 46: 1422-1430, 2015.
76. Liesz A, Roth S, Zorn M, Sun L, Hofmann K, and Veltkamp R. Acquired Immunoglobulin G deficiency in stroke patients and experimental brain ischemia. Exp Neurol 271: 46-52, 2015.
77. Liesz A, Ruger H, Purrucker J, Zorn M, Dalpke A, Mohlenbruch M, Englert S, Nawroth PP, and Veltkamp R. Stress mediators and immune dysfunction in patients with acute cerebrovascular diseases. PLoS One 8: e74839, 2013.
78. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, Giese T, and Veltkamp R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 15: 192-199, 2009.
79. Liesz A, Zhou W, Mracsko E, Karcher S, Bauer H, Schwarting S, Sun L, Bruder D, Stegemann S, Cerwenka A, Sommer C, Dalpke AH, and Veltkamp R. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 134: 704-720, 2011.
80. Liesz A, Zhou W, Na SY, Hammerling GJ, Garbi N, Karcher S, Mracsko E, Backs J, Rivest S, and Veltkamp R. Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. J Neurosci 33: 17350-17362, 2013.
81. Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo A, Borsellino G, Leoni O, Palumbo R, Battistini L, Rastaldo R, Muller S, Pompilio G, Anversa P, Bianchi ME, and Capogrossi MC. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 97: e73-e83, 2005.
82. Lin JZ, Miao KQ, Zhang HX, Kong QZ, Yuan RM, Wang ZW, and Liu SX. [Change of early serum TNF-alpha and IL-6 levels in acute cerebral infarction and its significances]. Zhejiang Da Xue Xue Bao Yi Xue Ban 39: 415-418, 2010 [In Chinese].
83. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 79: 1431-1568, 1999.
84. Longa EZ, Weinstein PR, Carlson S, and Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91, 1989.
85. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, Robinson M, Van Zoelen MA, Yang H, Li J, Erlandsson-Harris H, Chavan SS, Wang H, Andersson U, and Tracey KJ. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 111: 3068-3073, 2014.
86. Mander P, Borutaite V, Moncada S, and Brown GC. Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death. J Neurosci Res 79: 208-215, 2005.
87. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P, and Del Maschio A. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 180: 2270-2275, 2008.
88. Meagher LC, Cousin JM, Seckl JR, and Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156: 4422-4428, 1996.
89. Meisel C, Schwab JM, Prass K, Meisel A, and Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 6: 775-786, 2005.
90. Menini T, Ikeda H, Kimura S, and Gugliucci A. Circulating soluble RAGE increase after a cerebrovascular event. Clin Chem Lab Med 52: 109-116, 2014.
91. Mracsko E, Liesz A, Karcher S, Zorn M, Bari F, and Veltkamp R. Differential effects of sympathetic nervous system and hypothalamic-pituitary-adrenal axis on systemic immune cells after severe experimental stroke. Brain Behav Immun 41: 200-209, 2014.
92. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, and Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28: 12023-12031, 2008.
93. Murakami K, Koide M, Dumont TM, Russell SR, Tranmer BI, and Wellman GC. Subarachnoid hemorrhage induces gliosis and increased expression of the pro-inflammatory cytokine high mobility group box 1 protein. Transl Stroke Res 2: 72-79, 2011.
94. Nakahara T, Tsuruta R, Kaneko T, Yamashita S, Fujita M, Kasaoka S, Hashiguchi T, Suzuki M, Maruyama I, and Maekawa T. High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage. Neurocrit Care 11: 362-368, 2009.
95. Nathan C. Points of control in inflammation. Nature 420: 846-852, 2002.
96. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, and Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467-477, 2006.
97. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, and Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 26: 654-665, 2006.
98. Offner H, Vandenbark AA, and Hurn PD. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience 158: 1098-1111, 2009.
99. Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, Yoshino T, Ohtsuka A, Otani N, Tomura S, Shima K, Yamamoto Y, Yamamoto H, Takahashi HK, Mori S, and Nishibori M. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol 72: 373-384, 2012.
100. Park C, Cho IH, Kim D, Jo EK, Choi SY, Oh SB, Park K, Kim JS, and Lee SJ. Toll-like receptor 2 contributes to glial cell activation and heme oxygenase-1 expression in traumatic brain injury. Neurosci Lett 431: 123-128, 2008.
101. Peter C, Wesselborg S, Herrmann M, and Lauber K. Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis 15: 1007-1028, 2010.
102. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dirnagl U, Volk HD, and Meisel A. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 198: 725-736, 2003.
103. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, and Moskowitz MA. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 28: 927-938, 2008.
104. Qiu J, Xu J, Zheng Y, Wei Y, Zhu X, Lo EH, Moskowitz MA, and Sims JR. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 41: 2077-2082, 2010.
105. Ren X, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, and Offner H. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci 31: 8556-8563, 2011.
106. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE, Tracey KJ, and Wang H. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170: 3890-3897, 2003.
107. Said-Sadier N and Ojcius DM. Alarmins, inflammasomes and immunity. Biomed J 35: 437-449, 2012.
108. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, and Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 158: 4200-4210, 1997.
109. Sapojnikova N, Kartvelishvili T, Asatiani N, Zinkevich V, Kalandadze I, Gugutsidze D, Shakarishvili R, and Tsiskaridze A. Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. Biochim Biophys Acta 1842: 1379-1384, 2014.
110. Scaffidi P, Misteli T, and Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
111. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME, and Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209: 551-563, 2012.
112. Schulze J, Zierath D, Tanzi P, Cain K, Shibata D, Dressel A, and Becker K. Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 44: 246-248, 2013.
113. Sergeeva SP, Erofeeva LM, and Gul'tiaev MM. [IL-1beta, IL-10, INF-gamma, TNF-alpha, S100beta, AMA-M2 and cell immune response in stroke]. Patol Fiziol Eksp Ter 41-45, 2011 [In Russian].
114. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, Iwaki T, Okada Y, Iida M, Cua DJ, Iwakura Y, and Yoshimura A. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15: 946-950, 2009.
115. Sotgiu S, Zanda B, Marchetti B, Fois ML, Arru G, Pes GM, Salaris FS, Arru A, Pirisi A, and Rosati G. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 13: 505-513, 2006.
116. Spera PA, Ellison JA, Feuerstein GZ, and Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 251: 189-192, 1998.
117. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, Dantzer R, and Kelley KW. Interleukin-10 in the brain. Crit Rev Immunol 21: 427-449, 2001.
118. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev CD000197, 2007.
119. Sundberg E, Fasth AE, Palmblad K, Harris HE, and Andersson U. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 214: 303-309, 2009.
120. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, and Mattson MP. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 104: 13798-13803, 2007.
121. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, and Jacobson MF. Lifetime cost of stroke in the United States. Stroke 27: 1459-1466, 1996.
122. Tu XK, Yang WZ, Shi SS, Wang CH, Zhang GL, Ni TR, Chen CM, Wang R, Jia JW, and Song QM. Spatio-temporal distribution of inflammatory reaction and expression of TLR2/4 signaling pathway in rat brain following permanent focal cerebral ischemia. Neurochem Res 35: 1147-1155, 2010.
123. Tuttolomondo A, Di Sciacca R, Di Raimondo D, Serio A, D'Aguanno G, La Placa S, Pecoraro R, Arnao V, Marino L, Monaco S, Natale E, Licata G, and Pinto A. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. JNeuroimmunol215: 84-89, 2009.
124. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W; DECIMAL, DESTINY, and HAMLET investigators. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6: 215-222, 2007.
125. Vogelgesang A, May VE, Grunwald U, Bakkeboe M, Langner S, Wallaschofski H, Kessler C, Broker BM, and Dressel A. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One 5: e8718, 2010.
126. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, and Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
127. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, and Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392, 1999.
128. Wang J and Dore S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 27: 894-908, 2007.
129. Wang KY, Yu GF, Zhang ZY, Huang Q, and Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin Chim Acta 413: 1737-1741, 2012.
130. Wang L, Zhang X, Liu L, Yang R, Cui L, and Li M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett 471: 152-156, 2010.
131. Wang Q, Tang XN, and Yenari MA. The inflammatory response in stroke. J Neuroimmunol 184: 53-68, 2007.
132. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, and Feuerstein GZ. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol 23: 103-114, 1994.
133. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, and Sudlow C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 6: e1000145, 2009.
134. Wild CA, Bergmann C, Fritz G, Schuler P, Hoffmann TK, Lotfi R, Westendorf A, Brandau S, and Lang S. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol 24: 485-494, 2012.
135. Wong CH, Jenne CN, Lee WY, Leger C, and Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 334: 101-105, 2011.
136. Xanthis A, Hatzitolios A, Fidani S, Befani C, Giannakoulas G, and Koliakos G. Receptor of advanced glycation end products (RAGE) positively regulates CD36 expression and reactive oxygen species production in human monocytes in diabetes. Angiology 60: 772-779, 2009.
137. Xi G, Keep RF, and Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 5: 53-63, 2006.
138. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, and Taniguchi T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462: 99-103, 2009.
139. Yang GY, Gong C, Qin Z, Ye W, Mao Y, and Bertz AL. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 9: 2131-2134, 1998.
140. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, and Antoine DJ. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 18: 250-259, 2012.
141. Yang H, Wang H, Ju Z, Ragab AA, Lundback P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, and Al-Abed Y. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 212: 5-14, 2015.
142. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, Xiang J, Li JC, Fang CQ, and Wang JZ. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 31: 593-605, 2011.
143. Zhai DX, Kong QF, Xu WS, Bai SS, Peng HS, Zhao K, Li GZ, Wang DD, Sun B, Wang JH, Wang GY, and Li HL. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neurosci Lett 445: 117-121, 2008.
144. Zhan Y, Chen C, Suzuki H, Hu Q, Zhi X, and Zhang JH. Hydrogen gas ameliorates oxidative stress in early brain injury after subarachnoid hemorrhage in rats. Crit Care Med 40: 1291-1296, 2012.
145. Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, Grabe N, and Veltkamp R. Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. Brain Pathol 23: 34-44, 2013.
146. Zhou Y, Xiong KL, Lin S, Zhong Q, Lu FL, Liang H, Li JC, Wang JZ, and Yang QW. Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediators Inflamm 2010: pii:142458, 2010.